Search research articles
Contact Us
Filters
Showing results (111-120 of 125) with videos related to
Page
of 13
Sort By:
International Journal of Molecular Sciences
|
September 26, 2020
Development of a Rat Model for Glioma-Related Epilepsy
Charlotte Bouckaert, Charlotte Germonpré, Jeroen Verhoeven, et al.
Journal of Neuro-Oncology
|
November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Martin van den Bent, Analia Azaro, Filip De Vos, et al.
Neuro-Oncology
|
May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim, Michael Weller, Ahmed Idbaih, et al.
Neuro-Oncology Advances
|
November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Maria Vieito, Matteo Simonelli, Filip de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Neuro-Oncology
|
November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Neuro-Oncology Practice
|
May 14, 2026
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project
Evangelia Razis, Thierry Gorlia, Matthias Preusser, et al.
The Journal of Pathology
|
December 17, 2016
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis
Sophie Van Welden, Martine De Vos, Ben Wielockx, et al.
Neuro-Oncology
|
July 2, 2020
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin van den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 125) with videos related to
Sort By:
Page
of 13
International Journal of Molecular Sciences
|
September 26, 2020
Development of a Rat Model for Glioma-Related Epilepsy
Charlotte Bouckaert, Charlotte Germonpré, Jeroen Verhoeven, et al.
Journal of Neuro-Oncology
|
November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma
Martin van den Bent, Analia Azaro, Filip De Vos, et al.
Neuro-Oncology
|
May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim, Michael Weller, Ahmed Idbaih, et al.
Neuro-Oncology Advances
|
November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Maria Vieito, Matteo Simonelli, Filip de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 4, 2021
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, et al.
Neuro-Oncology
|
November 21, 2019
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin Van Den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2020
<i>BRAF</i>-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton, Yiqun Yang, Catarina D Campbell, et al.
Neuro-Oncology Practice
|
May 14, 2026
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project
Evangelia Razis, Thierry Gorlia, Matthias Preusser, et al.
The Journal of Pathology
|
December 17, 2016
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis
Sophie Van Welden, Martine De Vos, Ben Wielockx, et al.
Neuro-Oncology
|
July 2, 2020
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin van den Bent, Marica Eoli, Juan Manuel Sepulveda, et al.
Page
of 13